Celltrion: “Zympentra Shows Consistent Therapeutic Effect Across All Intestinal Inflammatory Sites”
Celltrion announced that its autoimmune disease therapy Zympentra—the U.S. brand name for the subcutaneous (SC) formulation of Remsima…
Celltrion
22 개의 기사가 있습니다.
Celltrion Bets on Oral Obesity Drug: “The Wegovy Era Won’t Last Long”
Celltrion is set to enter the growing market for oral obesity drugs, aiming to overcome the limitations of…
Fierce ADC Battlefield… Celltrion’s Bet Is on ‘biobetter’
Celltrion, which has entered the rapidly emerging field of antibody–drug conjugates (ADCs), is seeking to differentiate itself with…
Celltrion Wins Successive Bids in Italian Regional Drug Tenders
Celltrion is expanding its presence in Italy as its autoimmune disease treatments and cancer therapies continue to secure…
“Beyond Biosimilars”…Celltrion Moves into New Drug Development
Celltrion is accelerating its transition from a biosimilar-focused strategy to full-scale new drug development. With successive approvals for…
Celltrion “Remsima SC captures 22% market share in Europe”
Celltrion’s Remsima SC is solidifying its position as a leading autoimmune disease treatment in Europe. On May 28,…
Celltrion’s Yuflyma Gains FDA Interchangeability with Humira
Celltrion’s autoimmune disease treatment Yuflyma can now be used as an interchangeable substitute for Humira in the United…
Celltrion Secures FDA IND for ADC Cancer Therapy…First Step in New Drug Development
Celltrion has taken its first step as a new drug developer. Celltrion announced on the 5th that it…
Celltrion’s Bone Disease Biosimilar Wins FDA Approval in the U.S.
Celltrion announced on the 4th that its bone disease treatment biosimilars Stoboclo and Osenvelt—biosimilars of Prolia and Xgeva…
Celltrion’s Achievement: Remsima Becomes Korea’s First Global Blockbuster Drug
Celltrion's autoimmune disease treatment, Remsima (ingredient: infliximab), has surpassed annual sales of 1.2 trillion KRW, becoming Korea’s first…